Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
Résumé
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic disease the 5-year survival rate is approximately 5%. To help accelerate the
Fichier principal
Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer.pdf (1.41 Mo)
Télécharger le fichier
Origine | Fichiers produits par l'(les) auteur(s) |
---|